time

Session title

Session description

10:00 - 11:30

Digital Therapeutics (DTx)

Covid-19 has drastically accelerated the adoption of digital health solutions. The increased utilization of digital therapeutics has shown to ease the burden faced by the healthcare system during the pandemic. This shift towards digital adoption has put pressure on pharma to innovate beyond their traditional approaches.

1. What should DTx/Pharma companies look for when establishing partnerships?
2. What are the challenges being seen in these partnerships?
3. How are partnerships being used to drive DTx adoption?
4. What does the future of DTx partnerships potentially look like?

11:30 - 13:00

Real World Evidence

 With the exponentially increasing array of data generated outside of classic clinical trials, the evidence we can gleam from them is playing an increasingly important role in all areas of the healthcare value chain.

Efficient use of these real world evidence (RWE) is seen by many leaders as the next huge step in medical product development and validation. Whilst definitely not without possible concerns, RWE presents countless benefits over randomised controlled trials and are particularly useful in guiding healthcare decision making. Only by learning from real life scenarios can we accurately evaluate how effective anything truly is.

13:00 - 14:30

Decentralised virtual Clinical Trials

The pandemic has accelerated the rate at which real-world data and digital tools have been adopted to conduct clinical trials. The pandemic coupled with the appropriate technologies have caused a fundamental shift towards decentralized virtual clinical trials. Resulting in rich data sets invaluable for researching a wide range of interventions, variables, and specific patient populations.

1. What are the differences between traditional and virtual clinical trials?
2. How do DTx solutions assist in running virtual/hybrid clinical trials?
3. How do we assess the value of DTx solutions through clinical trials?
4. What are the current challenges being experienced in this space?

Transforming healthcare through AI drug discovery 

Many vibrant new companies challenge the traditional drug discovery methods of ‘Big Pharma’ by harnessing the power of computers and AI. But is it the case that for much 'AI' drug discovery, the data has already been processed by traditional pharmaceutical companies?

Learn in this module about how AI drug design is changing the paradigm of drug discovery

15:30 - 17:30

How global Pharma companies can adapt digital innovations to maximise success

Addressing the digital skills and innovation gap needed for global Pharma businesses

- Fully immersive and engaged learning
- Its about empowering your people
- Being realistic and delivering enduring change